

Update on Pharmacoeconomics in the Irish Healthcare Setting



Date: 21st & 22nd March 2018

Venue: Dublin Castle

DAY ONE

Morning Session

9am Opening session	Minister S. Harris
9.30-10.15	Pharmacoeconomics Update Prof M. Barry (Clinical Director NCPE and Clinical Lead of the MMP)
10.15-10.35	HTA: The Industry Perspective TBC
10.35-11.00	HTA: The Payer Perspective S. FLanagan (Chief Pharmacist, CPU)
11.00-11.30	BREAK
11.30-12.00	Efficacy and effectiveness assessment for HTA evaluations Dr A.O'Leary (Chief II Pharmacist at the NCPE)
12.00-12.30	HTA of drugs with limited clinical evidence Prof C.Walsh (Professor in Statistics, University of Limerick)
12.30-13.00	Delphi panel: Lessons on best practice C. Ni Choitir (Health Technology Assessor)

Afternoon Session

14.00-14.30	NCPE Assessments of oncology drugs Prof M. Barry (Clinical Director NCPE and Clinical Lead of the MMP)
14.30-15.00	HTA of oncology drugs: The clinician perspective (Prof J. Kennedy, Consultant Medical Oncologist)
BREAK 15.00-15.15	
15.15-15.45	The challenge of assessing drugs with multiple indications (D. Tyas, Director of Health Economic and Outcomes Research BMS)
Research:	
15.45-16.15	Evaluation of drugs for melanoma C. Gorry (Health Technology Assessor)
16.15-16.45	Evaluation of the PCSK9s H O'Donnell (Health Technology Assessor)

DAY TWO

Morning Session

9AM-10.30 AM (PARALLEL SESSIONS): Please choose one (A or B) and contact NCPE with your choice.

Patient involvement in HTA (parallel session)		Statistics	
A		B	
9.00-9.15	Patient submissions to the NCPE C. Gorry (Health Technology Assessor)	9.00-9.30	Survival analysis Dr. F. Lamrock (Statistician)
9.15-9.30	Overview of the EUPATI programme Prof L. McCullagh Associate (Professor in Pharmacoeconomics and HTA)	9.30-10.00	Statistical considerations in HTA submissions Dr. A White (Assistant Professor in Statistics)
9.30-9.50	The Patient Perspective of the EUPATI Programme. Rachel Lynch (Patient Representative Fibrolreland)	10.00-10.30	Role of the statistician in the assessment process Prof C. Walsh (Professor in Statistics University of Limerick)
9.50-10.30	Healthcare Decisions: Making the Patient's Voice Heard'. Representatives from some of Ireland's patient advocacy groups discuss innovative ways of involving the patient voice directly in decision making.		

BREAK (10.30-11AM)

- 11.00-11.20** NCPE process update – new terminology
Dr E. Fogarty (Senior Health Technology Assessor)
- 11.20-11.40** Overview of NCPE Rapid review process
Dr L. Tilson (Deputy Head of NCPE)
- 11.40-12.00** Research on rapid review process
Dr A. Murphy (Lecturer in Economics)
- 12.00-12.30** New antimicrobial agents: The clinical perspective
- 12.30-13.00** HTA of antimicrobial agents
Dr E. Fogarty (Senior Health Technology Assessor)

Afternoon Session

- 14.00-14.30** HTA at HIQA / CICER Programme / Role of Chair of EUnetHTA Assembly
Dr M. Ryan (Deputy Chief Executive of HIQA and Director of HTA)
- 14.30-15.00** HTA in Europe: EUnetHTA, BENELUXA, Valetta
Dr C. Usher (Senior Health Technology Assessor)
- 15.00-15.30** Review of HTA recommendations in the context of the IPHAgreement decision making framework
Professor L. McCullagh (Associate Professor of Pharmacoeconomics and HTA)
- Post HTA drug utilisation analysis / budget impact analysis
Dr. F. Lamrock (Statistician at the NCPE)
- 15.30-16.00** Update on Medicines Management Programme
Prior authorisation / how MMP manage versatis / entresto etc
Professor M. Barry (Director of the NCPE and clinical lead of the MMP)

Closing Remarks Professor M. Barry